Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibroblasts (CAFs) are a prominent cell type and a source of resistance to cancer therapies. Here, we...

Histone deacetylase inhibitors in cancer therapy.

Histones are a family of nuclear proteins that interact with DNA, resulting in DNA being wrapped around a core of histone octamer within the nucleosome. Acetylation/deacetylation of histones is an important mechanism that regulates gene expression and chromatin remodeling. Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic drugs that regulate gene expression by enhancing ...

Histone deacetylase inhibitors in cancer treatment.

Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential anticancer agents for the treatment of solid and hematological malignancies. In recent years, an increasing number of structurally diverse HDAC inhibitors have been identified that inhibit proliferation and induce differentiation and/or apoptosis of tumor cells in culture and in animal models. HDAC inhibiti...

Acetylation and Histone Deacetylase Inhibitors in Cancer

In recent years, the role of epigenetics in the development and treatment of cancer has gained interest and the effects of internal and external factors on the epigenetic profile are under investigation. The term “epigenetics” refers to modifications that influence phenotype without altering genotype. Epigenetic changes are potentially reversible but generally stably maintained during the cell ...

a structure–activity relationship survey of histone deacetylase (hdac) inhibitors